Third Wave Technologies IPO Will Fund Diagnostic Genotyping Tests
This article was originally published in The Gray Sheet
Executive Summary
Third Wave Technologies intends to develop clinical diagnostic tests for several inherited and infectious diseases, the firm said in its July 31 prospectus detailing a $100 mil. initial public offering.
You may also be interested in...
Breast, Prostate Imaging Regimens Would Be Aided By GEMS/Genometrix
GE Medical Systems will combine its molecular diagnostic imaging platform with Genometrix' microarray gene and protein analysis technology to develop biomarkers for breast and prostate cancer.
Breast, Prostate Imaging Regimens Would Be Aided By GEMS/Genometrix
GE Medical Systems will combine its molecular diagnostic imaging platform with Genometrix' microarray gene and protein analysis technology to develop biomarkers for breast and prostate cancer.
PE Biosystems/Third Wave Technologies
Termination of a January acquisition pact under which PE Biosystems would have acquired the Madison, Wisconsin-based developer of nucleic acid technologies for stock valued in the $300 mil. range will not prevent the firms from continuing to pursue joint collaborations, including several active projects, PE says (1"The Gray Sheet" Jan. 31, p. 19). "Recent discussions...led both companies to conclude that their collective interests would be best served if the companies remain independent but continue to collaborate," PE says in a May 25 release